Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of indolines and biindoles. It is structurally related to indirubin derivatives and has been studied primarily as a kinase inhibitor in structural biology research. The molecule has been co-crystallized with several protein kinases in the Protein Data Bank (PDB), including human calcium/calmodulin-dependent protein kinase type II alpha (CAMK2A) and PCTAIRE1 kinase. Its mechanism of action involves binding to the ATP-binding pocket of kinases as an inhibitor; however, it is not an approved pharmaceutical drug and remains experimental with no established clinical indications[1][4][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2Z,3E)-2,3'-biindole-2',3(1H,1'H)-dione 3-{O-[(3R)-3,4-dihydroxybutyl]oxime}.